About China Biologic Products Holdings
China Biologic Products Holdings is a company based in Guiyang (China) founded in 2002 was acquired by Centurium Capital in April 2021.. China Biologic Products Holdings has raised $300 million across 2 funding rounds from investors including Abu Dhabi Investment Authority, GIC and China Life Private Equity. The company has 1 employees as of December 31, 2019. China Biologic Products Holdings has completed 1 acquisition, including Tianxinfu Medical Equipment. China Biologic Products Holdings operates in a competitive market with competitors including Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
- Headquarter Guiyang, China
- Employees 1 as on 31 Dec, 2019
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name China Biologic Products, Inc.
-
Annual Revenue
$341.17 M15as on Dec 31, 2016
-
Net Profit
$128.79 M13as on Dec 31, 2016
-
EBITDA
$143.91 M9as on Dec 31, 2016
-
Total Equity Funding
$300 M (USD)
in 2 rounds
-
Latest Funding Round
$300 M (USD), Series D
Aug 02, 2022
-
Investors
Abu Dhabi Investment Authority
& 3 more
-
Employee Count
1
as on Dec 31, 2019
- Investments & Acquisitions
-
Acquired by
Centurium Capital
(Apr 21, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of China Biologic Products Holdings
China Biologic Products Holdings has successfully raised a total of $300M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $300 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series D — $300.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Series D - China Biologic Products Holdings | Valuation | ADIA , GIC | |
| Jun, 2018 | Amount | Seed - China Biologic Products Holdings | Valuation | Centurium Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in China Biologic Products Holdings
China Biologic Products Holdings has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Abu Dhabi Investment Authority, GIC and China Life Private Equity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Founded Year | Domain | Location | |
|
Private equity investments are managed from bases in China.
|
Founded Year | Domain | Location | |
|
Centurium Capital is focused on industrial investments in key sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by China Biologic Products Holdings
China Biologic Products Holdings has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tianxinfu Medical Equipment. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Orthopedic joint and spinal products with regenerative materials are developed.
|
2002 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - China Biologic Products Holdings
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
China Biologic Products Holdings Comparisons
Competitors of China Biologic Products Holdings
China Biologic Products Holdings operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of hematologic diseases
|
|
| domain | founded_year | HQ Location |
Small molecules are developed to treat hematologic and musculoskeletal disorders.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating multiple diseases
|
|
| domain | founded_year | HQ Location |
Cancer therapeutics are developed using targeted gene editing platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on China Biologic Products Holdings
Frequently Asked Questions about China Biologic Products Holdings
When was China Biologic Products Holdings founded?
China Biologic Products Holdings was founded in 2002 and raised its 1st funding round 16 years after it was founded.
Where is China Biologic Products Holdings located?
China Biologic Products Holdings is headquartered in Guiyang, China. It is registered at Guiyang, Guizhou, China.
Is China Biologic Products Holdings a funded company?
China Biologic Products Holdings is a funded company, having raised a total of $300M across 2 funding rounds to date.
How many employees does China Biologic Products Holdings have?
As of Dec 31, 2019, the latest employee count at China Biologic Products Holdings is 1.
What is the annual revenue of China Biologic Products Holdings?
Annual revenue of China Biologic Products Holdings is $341.17M as on Dec 31, 2016.
What does China Biologic Products Holdings do?
Founded in 2002 and headquartered in Guiyang, China, the company operates as a fully integrated entity in the biopharmaceutical sector focused on plasma-derived products. Plasma collection is managed alongside research and development, manufacturing, and distribution. Key offerings include human albumin, intravenous immunoglobulins, hepatitis B immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, coagulation factor VIII, prothrombin complex concentrate, and placenta polypeptide. Operations emphasize plasma sourcing and product commercialization within China.
Who are the top competitors of China Biologic Products Holdings?
China Biologic Products Holdings's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
How many acquisitions has China Biologic Products Holdings made?
China Biologic Products Holdings has made 1 acquisition, including Tianxinfu Medical Equipment.
Who are China Biologic Products Holdings's investors?
China Biologic Products Holdings has 4 investors. Key investors include Abu Dhabi Investment Authority, GIC, China Life Private Equity, and Centurium Capital.